Methylpyrrolidone

Methylpyrrolidone

SCHEMBL1461340

CC(C)C(N)=O.CN1CCCC1=O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.65
BRD2 P25440 1/20 0.65
LMNA P02545 3/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA3 P07451 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
TSHR P16473 1/20 0.43
PIK3CD O00329 2/20 0.40
KMT2A Q03164 2/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylpyrrolidone SCHEMBL28231789 0.92 BRD4 (0.55) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL27799421 0.88 BRD4 (0.77) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL6251574 0.86 BRD4 (0.74) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL3004368 0.84 BRD4 (0.77) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL28229116 0.84 BRD4 (0.77) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL28252843 0.82 CA1 (0.57) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL10701586 0.81 BRD4 (0.81) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL2243830 0.81 BRD4 (0.81) BRD4BRD2LMNACA12CA1
Methylpyrrolidone SCHEMBL7170191 0.81
Methylpyrrolidone SCHEMBL1368701 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113314746-B Cross-linked functionalized polyvinyl alcohol anion exchange membrane and preparation method thereof 温州黑鹰网络科技有限公司 2022-09-09 CN claimed
CN-114874621-A Low-dielectric-conductivity thermal polyimide film and preparation method thereof 纳电(深圳)材料科技有限公司 2022-08-09 CN claimed
CN-113314746-A Cross-linked functionalized polyvinyl alcohol anion exchange membrane and preparation method thereof 温州黑鹰网络科技有限公司 2021-08-27 CN claimed
WO-2015137914-A1 METHODS FOR PRODUCING NYLON 7 EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2015-09-17 WO claimed
US-5003103-A Decarboxylation, chlorodenitration, catalysis OCCIDENTAL CHEMICAL CORPORATION (US) 1991-03-26 US claimed
CN-117545757-A 5-oxo-pyrido [2,3-d ] pyridazin-6 (5H) -ylacetamides 詹森药业有限公司 2024-02-09 CN disclosed
US-11786534-B2 Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-10-17 US disclosed
EP-4153556-A1 METHOD FOR PREPARING ACRYLIC ACID FROM BETA-PROPIOLACTONE Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2023-03-29 EP disclosed
CN-112375010-B Novel diamine, polyimide and polyimide film 浙江中科玖源新材料有限公司 2023-03-10 CN disclosed
CN-113314746-B Cross-linked functionalized polyvinyl alcohol anion exchange membrane and preparation method thereof 温州黑鹰网络科技有限公司 2022-09-09 CN disclosed
US-11384121-B2 Creation of peptide-based anti-tumor agent NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2022-07-12 US disclosed
WO-2021233839-A1 METHOD FOR PREPARING ACRYLIC ACID FROM β-PROPIOLACTONE COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2021-11-25 WO disclosed
EP-0358395-A2 Aromatic imide polymer fiber-reinforced prepreg and cured resinous laminate material derived from same UBE INDUSTRIES, LTD. (JP) 1990-03-14 EP disclosed
US-4801502-A SERRATED FIBERS-WOOL LIKE CHEMIEFASER LENZING AKTIENGESELLSCHAFT (AT) 1989-01-31 US disclosed
US-4707400-A WATERPROOFING, PERMEABILITY, COATINGS, FABRICS, POLYURETHANES, ACRYLIC ACID POLYMER BURLINGTON INDUSTRIES, INC. (US) 1987-11-17 US disclosed
US-4598091-A (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds DEGUSSA AKTIENGESELLSCHAFT (DE) 1986-07-01 US disclosed
EP-0000924-B1 HETEROCYCLIC PHENYL ETHERS AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1981-04-29 EP disclosed
US-4145532-A TERTIARY AMINE OXIDE SOLVENT AKZONA INCORPORATED (US) 1979-03-20 US disclosed
EP-0000924-A1 Heterocyclic phenyl ethers and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1979-03-07 EP disclosed
US-4076694-A FROM A POLYISOCYANATE AND A SUBSTITUTED CYCLIC CARBOXYLIC ACID ANHYDRIDE BAYER AKTIENGESELLSCHAFT (DT) 1978-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384121-B2 Creation of peptide-based anti-tumor agent NGLY1, VIP, ETF1 BRD4 3134/4885BRD2 4559/4885LMNA 3049/4885
US-11786534-B2 Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors EGFR, ERBB2, ERBB3 BRD4 618/4885BRD2 909/4885LMNA 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.